LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 8 of 15: Cell count and normalized growth rate inhibition values within biological replicate 1. - Dataset (ID:20245)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | GSK1904529A | 0.12 | uM | LJP6 | 3 | H23 | 72 | hr | 1476 | 3363 | 3734 | 0.9006 | 0.8496 |
| SK-BR-3 | GSK1904529A | 0.37 | uM | LJP6 | 1 | H22 | 72 | hr | 1476 | 3246 | 3413 | 0.9510 | 0.9186 |
| SK-BR-3 | GSK1904529A | 0.37 | uM | LJP6 | 2 | H22 | 72 | hr | 1476 | 3662 | 3783 | 0.9679 | 0.9525 |
| SK-BR-3 | GSK1904529A | 0.37 | uM | LJP6 | 3 | H22 | 72 | hr | 1476 | 3883 | 3734 | 1.0399 | 1.0593 |
| SK-BR-3 | GSK1904529A | 1.11 | uM | LJP6 | 1 | H21 | 72 | hr | 1476 | 3366 | 3413 | 0.9862 | 0.9771 |
| SK-BR-3 | GSK1904529A | 1.11 | uM | LJP6 | 2 | H21 | 72 | hr | 1476 | 3648 | 3783 | 0.9642 | 0.9470 |
| SK-BR-3 | GSK1904529A | 1.11 | uM | LJP6 | 3 | H21 | 72 | hr | 1476 | 3405 | 3734 | 0.9119 | 0.8668 |
| SK-BR-3 | GSK1904529A | 3.33 | uM | LJP6 | 1 | H20 | 72 | hr | 1476 | 3460 | 3413 | 1.0137 | 1.0226 |
| SK-BR-3 | GSK1904529A | 3.33 | uM | LJP6 | 2 | H20 | 72 | hr | 1476 | 3800 | 3783 | 1.0044 | 1.0064 |
| SK-BR-3 | GSK1904529A | 3.33 | uM | LJP6 | 3 | H20 | 72 | hr | 1476 | 3814 | 3734 | 1.0214 | 1.0319 |
| SK-BR-3 | GSK1904529A | 10 | uM | LJP6 | 1 | H19 | 72 | hr | 1476 | 3426 | 3413 | 1.0037 | 1.0062 |
| SK-BR-3 | GSK1904529A | 10 | uM | LJP6 | 2 | H19 | 72 | hr | 1476 | 3737 | 3783 | 0.9877 | 0.9819 |
| SK-BR-3 | GSK1904529A | 10 | uM | LJP6 | 3 | H19 | 72 | hr | 1476 | 3973 | 3734 | 1.0640 | 1.0949 |
| SK-BR-3 | Linsitinib | 0.04 | uM | LJP5 | 1 | O24 | 72 | hr | 1476 | 2556 | 3788 | 0.6747 | 0.4972 |
| SK-BR-3 | Linsitinib | 0.04 | uM | LJP5 | 2 | O24 | 72 | hr | 1476 | 2656 | 3731 | 0.7118 | 0.5511 |
| SK-BR-3 | Linsitinib | 0.04 | uM | LJP5 | 3 | O24 | 72 | hr | 1476 | 2584 | 3796 | 0.6806 | 0.5079 |
| SK-BR-3 | Linsitinib | 0.12 | uM | LJP5 | 1 | O23 | 72 | hr | 1476 | 2933 | 3788 | 0.7742 | 0.6567 |
| SK-BR-3 | Linsitinib | 0.12 | uM | LJP5 | 2 | O23 | 72 | hr | 1476 | 3047 | 3731 | 0.8166 | 0.7189 |
| SK-BR-3 | Linsitinib | 0.12 | uM | LJP5 | 3 | O23 | 72 | hr | 1476 | 2812 | 3796 | 0.7407 | 0.6044 |
| SK-BR-3 | Linsitinib | 0.37 | uM | LJP5 | 1 | O22 | 72 | hr | 1476 | 3053 | 3788 | 0.8058 | 0.7063 |
| SK-BR-3 | Linsitinib | 0.37 | uM | LJP5 | 2 | O22 | 72 | hr | 1476 | 3053 | 3731 | 0.8182 | 0.7214 |
| SK-BR-3 | Linsitinib | 0.37 | uM | LJP5 | 3 | O22 | 72 | hr | 1476 | 3191 | 3796 | 0.8405 | 0.7605 |
| SK-BR-3 | Linsitinib | 1.11 | uM | LJP5 | 1 | O21 | 72 | hr | 1476 | 2697 | 3788 | 0.7119 | 0.5576 |
| SK-BR-3 | Linsitinib | 1.11 | uM | LJP5 | 2 | O21 | 72 | hr | 1476 | 3190 | 3731 | 0.8550 | 0.7788 |
| SK-BR-3 | Linsitinib | 1.11 | uM | LJP5 | 3 | O21 | 72 | hr | 1476 | 2877 | 3796 | 0.7578 | 0.6316 |